**Long-acting Benzodiazepine- Xanax XR (alprazolam, extended release)**

|  |  |
| --- | --- |
| Criteria 1 | Xanax XR (alprazolam, extended release) |

|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Long-acting Benzodiazepine | | |
| **Criteria Subtitle** | Xanax XR (alprazolam, extended release) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code (s) | Type of Code (GCNSeqNo, HICL, NDC) |
| XANAX XR | 050399 | GCNSeqNo |
| XANAX XR | 050400 | GCNSeqNo |
| XANAX XR | 050401 | GCNSeqNo |
| XANAX XR | 052143 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 1234 |
| 2 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 3 | 1000 |  | Select and Free Text | Has the patient had an inadequate clinical response to other benzodiazepines or is the patient transitioning from other benzodiazepines to alprazolam ER?  If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 4 | 1234 |  | Select and Free Text | Has the patient experienced clinical response with the requested medication?    If yes, please provide documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 5 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Initial authorizations will be for 180 days. Subsequent authorizations will be for 180 days and requires documentation of clinical response.

|  |  |
| --- | --- |
| **Last Approved** | 4/13/2023 |
| **Other** |  |